TP53 and neoplasm: Genetic modulation of SET by shRNA impaired cancer cell viability in a p53-dependent manner, indicating that SET plays a critical oncogenic role in the regulation of p53 in this tumor and it may represent an anti-neoplastic target for this disease [113].